Cellular Origins, a cell and gene therapy manufacturer, has appointed Geoffrey Hodge to its Board as the Non-Executive Director.
Geoff’s appointment will aim to fulfil the company’s strategic vision of accelerated growth, as well as boost the company’s commercial success.
Hodge was most recently the CEO of Sotio Biotech and the CTO of Unum Therapeutics, which were both companies involved in producing autologous stem cell therapies.
Before settling in the cell therapy sector, Geoff co-founded Xcellerex, which was valued at USD $50m before being sold to GE Healthcare.
As well as being on Cellular Origins’ executive board, Geoff will remain part of the company’s scientific advisory board too — where his experience in developing bio manufacturing technology will shape Cellular Origins’ future strategy.
Geoff will work alongside the leadership team to advance the company’s robotic platform, Constellation, which facilitates the manufacture of cell therapies in a more cost-effective and compact way.
Dr Edwin Stone, CEO at Cellular Origins, said: “Geoff has unique experience having built businesses that have transformed bioprocess manufacturing. There are very few individuals who have been through this journey. At Cellular Origins, we know how important it is to our customers that we can deliver solutions they can rely on and trust for the manufacturing of important therapies. Geoff’s expertise in building a business that was successful in doing this will be invaluable to Cellular Origins. His guidance, technical and commercial insight and industry network are, and will continue to be, a crucial asset as we realise our ambition to achieve faster, cost-effective and efficient routes to scalable manufacture of cell therapies.”
